More Than Half of Synthetic Cannabinoid-Related Emergency Department Visits Involve No Other Drugs

Estimated Percentage of U.S. Emergency Department Visits Involving Synthetic Cannabinoids and Bath Salts Alone and With Other Drugs, 2011

The majority of synthetic cannabinoid-related emergency department (ED) visits in 2011 involved no other drugs, according to recently released data from the national Drug Abuse Warning Network (DAWN). Of the estimated 28,531 ED visits involving a synthetic cannabinoid (the active chemical used in the production of Spice, synthetic marijuana, herbal incense, potpourri, etc) product, 57% were for synthetic cannabinoids alone, and only 13% involved two or more substances in addition to the synthetic cannabinoids. In contrast, only one-third (33%) of the estimated 22,904 bath salt-related ED visits involved bath salts alone, while more than one-third (36%) involved two or more substances combined with bath salts—nearly three times the rate for synthetic cannabinoid-related ED visits involving two or more other substances. 

Estimated Percentage of U.S. Emergency Department Visits Involving Synthetic Cannabinoids and Bath Salts Alone and With Other Drugs, 2011

Estimated Percentage of U.S. Emergency Department Visits  Involving Synthetic Cannabinoids and Bath Salts Alone and With Other Drugs, 2011

SOURCE: Adapted by CESAR from data from the Substance Abuse and Mental Health Data Archive, online analysis of the 2011 Drug Abuse Warning Network (DAWN) data set, conducted 9/18/2013. The SAMHDA is available online at http://www.icpsr.umich.edu/SAMHDA.


Share Your Story With Us

If you have firsthand experience with synthetic marijuana and are willing to share your story, you can help other people to gain new insights into their own struggle with this awful drug.

Name You Want To Be Used (Required)

Your Email (Required)

Your Story

Can We Anonymously Post Your Story To Help Others?
(Required)
YesNo

Type The Letters In The Box

captcha

   

Let's Stay In Touch!

Subscribe to get the latest submitted stories delivered to your inbox. Join Our Mailing List